ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0116

Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI

Chun Li1, Jianping Guo2, Yangyi Fan1, Yu Kang1 and Xiaodan Hu1, 1Peking University People's Hospital, Beijing, China (People's Republic), 2Peking University People's Hospital, Beijing, Beijing, China

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, Magnetic resonance imaging (MRI)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Cerebrovascular diseases are common and severe neurological complications in antiphospholipid syndrome (APS). However, few studies focused on cerebral small vessel disease (cSVD) in APS. We undertook this study to investigate the subtypes, the total burden on MRI and potential risk factors for cSVD in APS.

Methods: We retrospectively analyzed the medical records and brain magnetic resonance imaging (MRI) scans of patients with APS who visited our hospital between January 2015 and July 2022. An age and gender-matched healthy control group were recruited from the Health Care Center affiliated with Peking University People’s Hospital. Four major cSVD markers on MRI were assessed, including lacune, enlarged perivascular space (EPVS), microbleed and white matter hyperintensities (WMH). Total cSVD score, ranging from 0 to 4, were rated using validated visual scales. Univariate and multivariate logistic regression model was applied to analyze the association between clinical and laboratory indices and cSVD risks in APS.

Results: Among 132 enrolled patients, 76.5% (101/132) were females with a mean age of 47.0 years. 26.5% (35/132) were primary APS, and 51.5% (68/132) exhibited at least one of the cSVD markers. Lacune was the most frequent cSVD marker [46.2% (61/132)], followed by moderate-to-severe WMH [16.7% (22/132)], EPVS [14.4% (19/132)] and microbleed [12.1% (16/132)]. After adjusting for age, gender and disease duration, the cSVD was significantly associated with hypertension (OR 3. 688, 95%CI 1.17-11.65, P = 0.026), the incidence of thrombosis events (OR 22.145, 95%CI 2.11-232.27, P = 0.010), and the history of stroke (OR 10.709, 95%CI 2.47-46.36, P = 0.002).

Conclusion: In the present study, we observed a high incidence of cSVD in patients with APS. Hypertension, thrombotic events and the history of stroke are risk factors for cSVD in APS.


Disclosures: C. Li: None; J. Guo: None; Y. Fan: None; Y. Kang: None; X. Hu: None.

To cite this abstract in AMA style:

Li C, Guo J, Fan Y, Kang Y, Hu X. Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cerebral-small-vessel-disease-in-antiphospholipid-syndrome-subtypes-and-total-burden-of-csvd-on-mri/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cerebral-small-vessel-disease-in-antiphospholipid-syndrome-subtypes-and-total-burden-of-csvd-on-mri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology